Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections is a research paper published in Advanced Science (2024). On theSindex it has a DataRank of 0. It has been cited 13 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01AI165853
National Institutes of Health
Grant: R43AI155185
National Institutes of Health
Grant: R44AI141054
National Institutes of Health
Grant: R44AI138728
National Institutes of Health
Grant: R43AI149894
David and Lucile Packard Foundation
Grant: 2013‐39274
National Science Foundation
Grant: DMS‐2028758
National Institutes of Health
Grant: 1R43AI155185-01
Inhaled 'muco-trapping' antibody as universal immunotherapy for influenza virus infections
National Institutes of Health
Grant: 1R43AI149894-01A1
Aerosol immunotherapy for treatment of human metapneumovirus infection
National Institutes of Health
Grant: 4R44AI141054-02
Development of RespiraClear for targeted mucosal treatment of RSV infections
National Institutes of Health
Grant: 5R01AI165853-04
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections
National Institutes of Health
Grant: 5R44AI138728-03
In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of RSV
National Institutes of Health
Grant: 3UL1TR002489-02S1
North Carolina Translational and Clinical Science Institute (NC TraCS)
National Science Foundation
Grant: 2028758
RAPID: A Lung Mucus Strategy for COVID-19 Viral Protection
FWCI
3.75
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals